Zydus Company Profile
✉ Email this page to a colleague
What is the competitive landscape for ZYDUS
ZYDUS has four hundred and eleven approved drugs.
There is one US patent protecting ZYDUS drugs. There are twenty-eight tentative approvals on ZYDUS drugs.
Summary for Zydus
| US Patents: | 1 |
| Tradenames: | 329 |
| Ingredients: | 319 |
| NDAs: | 411 |
| Patent Litigation for Zydus: | See patent lawsuits for Zydus |
Drugs and US Patents for Zydus
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Zydus Lifesciences | DAPSONE | dapsone | TABLET;ORAL | 220103-002 | Feb 26, 2026 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Zydus Pharms Usa | RIBAVIRIN | ribavirin | TABLET;ORAL | 077094-001 | Dec 5, 2005 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Zydus Lifesciences | FELBAMATE | felbamate | TABLET;ORAL | 208970-001 | May 30, 2017 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Paragraph IV (Patent) Challenges for ZYDUS drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | for Injection | 200 mcg/vial | ➤ Subscribe | 2015-05-01 |
| ➤ Subscribe | for Injection | 100 mcg/vial and 500 mcg/vial | ➤ Subscribe | 2015-04-14 |
| ➤ Subscribe | Delayed-release Tablets | 20 mg | ➤ Subscribe | 2015-06-03 |
International Patents for Zydus Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Philippines | 12016501686 | ⤷ Start Trial |
| South Africa | 201606075 | ⤷ Start Trial |
| World Intellectual Property Organization (WIPO) | 2015128877 | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Zydus Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0296749 | 97C0023 | France | ⤷ Start Trial | PRODUCT NAME: ANASTROZOLE, EVENTUELLEMENT SOUS LA FORME D UN SEL D ADDITION ACCEPTABLE EN MEDECINE PHARMACEUTIQUE; NAT REG. NO/DATE: NL 21126 19961227; FIRST REG.: 12619/0106 19950811 |
| 1532149 | 132013902118390 | Italy | ⤷ Start Trial | PRODUCT NAME: LINAGLIPTIN + METFORMINA CLORIDRATO(JENTADUETO); AUTHORISATION NUMBER(S) AND DATE(S): DA EU/1/12/780/001 A EU/1/12/780/027, 20120720 |
| 1532149 | PA2012022 | Lithuania | ⤷ Start Trial | PRODUCT NAME: LINAGLIPTINUM + METFORMINI HYDROCHLORIDUM; REGISTRATION NO/DATE: EU/1/12/780/001 - EU/1/12/780/034 20120720 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
